Date: July 9, 2026

KMP / Board / Auditor Changes

Not Specified

Dividend Declaration or Non-Declaration

Not Specified

Board Meeting Outcomes

Not Specified

Financial Results (Standalone & Consolidated)

Not Specified

Disinvestment / Strategic Actions

Not Specified

Other Operational / Legal / Strategic Disclosures

Business Responsibility and Sustainability Report Disclosure

  • Filed pursuant to Regulation 34 of SEBI (LODR) Regulations, 2015
  • Covers financial year April 1, 2025 to March 31, 2026
  • Reporting boundary: Standalone basis
  • Assurance provider: BDO India Services Private Limited
  • Assurance type: Reasonable Assurance for BRSR Core Indicators

Company Details

  • Corporate office: Same as registered office
  • Paid-up capital: ₹12,82,98,890/-
  • Contact person: Ms. Sarada Bhamidipati, Company Secretary & Compliance Officer

Business Activities

  • Main activity: Manufacturing of Active Pharmaceutical Ingredients (100% of turnover)
  • Products: Development, manufacturing & sale of APIs & Custom Manufacturing Solutions (NIC Code: 21001)
  • Markets served: 11 Indian states, 59 international countries
  • Export contribution: 76% of revenue
  • Customer segments: Generic Drug Substances (GDS) and Custom Manufacturing Solutions (CMS)

Operations

  • Number of plants: 4 national (including R&D unit)
  • Number of offices: 1 national, 2 international
  • Total locations: 5 national, 2 international
  • New R&D location under lease arrangement (not operational during reporting period)

Employee Details (as of March 31, 2026)

  • Permanent employees: 2,097 (Male: 1,837, Female: 260)
  • Other than permanent employees: 374 (Male: 367, Female: 7)
  • Total employees: 2,471 (Male: 2,204, Female: 267)
  • Permanent workers: 86 (100% Male)
  • Other than permanent workers: 1,324 (Male: 1,234, Female: 90)
  • Total workers: 1,410 (Male: 1,320, Female: 90)
  • Differently abled employees: 1 permanent employee

Board Diversity

  • Board of Directors: 8 members with 1 female (12.50%)
  • Key Management Personnel: 2 with 1 female (50.00%)

Turnover Rates

  • Permanent employees: 14.30% (Male: 13.40%, Female: 16.10%)
  • Permanent workers: 0%

Subsidiaries

  • Neuland Laboratories Inc., USA (100% subsidiary)
  • Neuland Laboratories K.K., Japan (100% subsidiary)

CSR Details

  • CSR applicable: Yes
  • Turnover: ₹2,02,299 lakhs
  • Net worth: ₹1,86,498 lakhs
  • CSR spending: ₹609 lakhs

Grievance Redressal

  • Shareholders: 4 complaints (all resolved)
  • Employees and workers: 2 complaints (all resolved)
  • Other stakeholders: 0 complaints

Material ESG Issues

12 material topics identified through stakeholder survey including:

  • Human Capital Management (Opportunity)
  • Enterprise Risk Management & Business Continuity (Risk)
  • Product Quality & Regulatory Compliance (Risk)
  • GHG Emissions and Climate Change (Risk)
  • Green Chemistry & Sustainable Manufacturing (Opportunity)
  • Water Stewardship (Risk & Opportunity)
  • Energy Management (Risk & Opportunity)
  • Information & Cyber Security (Risk)
  • Waste & Effluent Management (Risk)
  • Digitalisation & AI Adoption (Opportunity)
  • Occupational health and Safety (Opportunity)

ESG Governance

  • Highest authority: Mr. Davuluri Sucheth Rao, Executive Vice Chairman
  • Committee: Risk and Sustainability (R&S) Committee
  • Policies cover all 9 NGRBC principles

Principle-wise Performance Highlights

Principle 1 (Ethical Business)

  • Anti-corruption policy in place with zero instances
  • Accounts payable days: 111 days (FY25: 136 days)
  • 18.77% purchases from trading houses

Principle 2 (Sustainable Products)

  • 1% of R&D spend on environmental/social improvements
  • 11.15% of capex on environmental/social improvements
  • 9.99% suppliers screened through ESG factors
  • Zero Liquid Discharge systems implemented

Principle 3 (Employee Well-being)

  • 100% employees covered by health insurance
  • 100% workers covered by health insurance
  • 0.62% of revenue spent on well-being measures
  • 100% coverage for PF and Gratuity
  • ISO 45001 certification for all sites
  • 0 safety incidents, fatalities, or high-consequence injuries

Principle 4 (Stakeholder Responsiveness)

  • Stakeholders include investors, customers, employees, value chain partners, community, governments
  • Double Materiality Assessment conducted in FY25-26

Principle 5 (Human Rights)

  • 100% employees and workers trained on human rights
  • All employees paid above minimum wage
  • 0 human rights complaints
  • 0 POSH complaints in FY26 (3 in FY25)

Principle 6 (Environmental Protection)

  • Total energy consumption: 4,72,771.75 GJ
  • Energy intensity: 0.000023 GJ/₹
  • Water consumption: 1,88,097.65 KL
  • Water intensity: 0.00000930 KL/₹
  • Scope 1 emissions: 29,324.15 tCO2e
  • Scope 2 emissions: 34,849.39 tCO2e
  • Total waste generated: 14,875.81 MT
  • 100% waste diverted from landfill
  • SBTi validation obtained

Principle 7 (Policy Influence)

  • Member of 6 industry associations including CII, Pharmaexcil, BDMA
  • 0 anti-competitive conduct issues

Principle 8 (Inclusive Growth)

  • 35.20% procurement from MSMEs/small producers
  • 77.89% procurement from within India
  • CSR projects benefiting 11,774+ people
  • Focus on healthcare, education, women empowerment, environment

Principle 9 (Consumer Responsibility)

  • 0 consumer complaints across all categories
  • ISO 27001:2022 certification for cybersecurity
  • 0 data breaches

Energy Conservation

  • Steps taken: Motor replacements, vacuum pump upgrades, capacitor banks
  • Alternate energy: Biomass briquettes usage (1,827 tons)
  • Capital investment: ₹817 lakhs on energy conservation
  • Power consumption: 487.95 lakh kWh (₹3,989.9 lakhs)
  • Coal consumption: 12,590.6 tonnes (₹1,138.97 lakhs)

Technology Absorption

  • R&D expenditure: ₹7,920.58 lakhs (Capital: ₹2,714.99 lakhs, Recurring: ₹5,205.59 lakhs)
  • 26 CMS projects completed, 10 ongoing
  • 19 GDS projects ongoing
  • 3 USDMFs filed, 3 CEP filings, 15 ROW filings
  • 17 patent applications filed

Foreign Exchange

  • Earnings: ₹1,47,538.51 lakhs
  • Outgo: ₹38,350.92 lakhs

Remuneration Details

  • Median employee remuneration: ₹6,60,000 (7.67% increase YoY)
  • Executive directors' remuneration ratio: 209-222 times median

Related Party Transactions

  • All transactions at arm's length basis
  • Total payments: ₹362.03 lakhs to related parties